MultiStem
Ischemic Stroke
Key Facts
About Athersys
Founded in 1995, Athersys has established itself as a leader in allogeneic, off-the-shelf cell therapy, with its MultiStem platform representing a significant technological advancement for acute care settings. The company's strategy focuses on advancing its lead asset, MultiStem, through late-stage clinical trials for ischemic stroke and ARDS, two areas with massive unmet need and limited treatment options. While facing financial and clinical execution challenges, Athersys's core value proposition lies in its scalable manufacturing and the immunomodulatory mechanism of its therapy, which has demonstrated potential in reducing inflammation and promoting repair. Its future hinges on securing strategic partnerships, achieving pivotal clinical milestones, and navigating a complex competitive and regulatory landscape.
View full company profileAbout Athersys
Founded in 1995, Athersys has established itself as a leader in allogeneic, off-the-shelf cell therapy, with its MultiStem platform representing a significant technological advancement for acute care settings. The company's strategy focuses on advancing its lead asset, MultiStem, through late-stage clinical trials for ischemic stroke and ARDS, two areas with massive unmet need and limited treatment options. While facing financial and clinical execution challenges, Athersys's core value proposition lies in its scalable manufacturing and the immunomodulatory mechanism of its therapy, which has demonstrated potential in reducing inflammation and promoting repair. Its future hinges on securing strategic partnerships, achieving pivotal clinical milestones, and navigating a complex competitive and regulatory landscape.
View full company profileAbout Athersys
Founded in 1995, Athersys has established itself as a leader in allogeneic, off-the-shelf cell therapy, with its MultiStem platform representing a significant technological advancement for acute care settings. The company's strategy focuses on advancing its lead asset, MultiStem, through late-stage clinical trials for ischemic stroke and ARDS, two areas with massive unmet need and limited treatment options. While facing financial and clinical execution challenges, Athersys's core value proposition lies in its scalable manufacturing and the immunomodulatory mechanism of its therapy, which has demonstrated potential in reducing inflammation and promoting repair. Its future hinges on securing strategic partnerships, achieving pivotal clinical milestones, and navigating a complex competitive and regulatory landscape.
View full company profileAbout Athersys
Founded in 1995, Athersys has established itself as a leader in allogeneic, off-the-shelf cell therapy, with its MultiStem platform representing a significant technological advancement for acute care settings. The company's strategy focuses on advancing its lead asset, MultiStem, through late-stage clinical trials for ischemic stroke and ARDS, two areas with massive unmet need and limited treatment options. While facing financial and clinical execution challenges, Athersys's core value proposition lies in its scalable manufacturing and the immunomodulatory mechanism of its therapy, which has demonstrated potential in reducing inflammation and promoting repair. Its future hinges on securing strategic partnerships, achieving pivotal clinical milestones, and navigating a complex competitive and regulatory landscape.
View full company profileTherapeutic Areas
Other Ischemic Stroke Drugs
| Drug | Company | Phase |
|---|---|---|
| IQool™ System | BrainCool | Clinical Evaluation |
| itMSCs + itNSCs | Stemedica Cell Technologies | Research |
| Ischemic Stroke Program | CHS Pharma | Pre-clinical |
| 3K3A-APC | ZZ Biotech | Phase 2/3 |
| Ischemic Stroke Device(s) | Infinity Neuro | Pre-clinical |
| THDG3 | DeckTherapeutics | Pre-clinical |
| Prometheus-based Gene Therapy | Remedium Bio | Pre-clinical |
| iNstroke Catheters | iVascularU | Commercial |
| Dual Thrombolytic Regimen (tPA + HisproUK) | Thrombolytic Science International | Phase 2 |
| Neural Stem Cell Therapy for Stroke | Neoneuron | Pre-clinical |
| RSLV-132 / Platform | Resolve Therapeutics | Pre-clinical / Research |
| BXT Oxygen Therapeutic | BioXyTran | Pre-clinical/Clinical |